Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Musculoskeletal stiffness? 374 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 374 reports of Musculoskeletal stiffness have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.6% of all adverse event reports for NATALIZUMAB.

374
Reports of Musculoskeletal stiffness with NATALIZUMAB
0.6%
of all NATALIZUMAB reports
2
Deaths
121
Hospitalizations

How Dangerous Is Musculoskeletal stiffness From NATALIZUMAB?

Of the 374 reports, 2 (0.5%) resulted in death, 121 (32.4%) required hospitalization, and 3 (0.8%) were considered life-threatening.

Is Musculoskeletal stiffness Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 374 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Multiple sclerosis relapse (6,478) Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948)

What Other Drugs Cause Musculoskeletal stiffness?

ADALIMUMAB (10,762) METHOTREXATE (9,903) ETANERCEPT (9,744) TOFACITINIB (7,354) TOCILIZUMAB (6,346) RITUXIMAB (6,058) LEFLUNOMIDE (6,031) ABATACEPT (5,926) SECUKINUMAB (5,655) HYDROXYCHLOROQUINE (5,271)

Which NATALIZUMAB Alternatives Have Lower Musculoskeletal stiffness Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Musculoskeletal stiffness Reports All Drugs Causing Musculoskeletal stiffness NATALIZUMAB Demographics